BioCryst Pharmaceuticals has signed a European licensing agreement with the Irish affiliate of Italian pharmaceutical company Neopharmed Gentili for the exclusive commercialisation of navenibart for hereditary angioedema, in a deal that could generate up to $345 million (€319 million) in total revenue, according to North Carolina Biological Center.

The agreement sees BioCryst partner with Neopharmed Gentili's Irish-registered affiliate as the designated European licensee, reinforcing Ireland's strategic role as a hub for pharmaceutical licensing and commercial operations across the European market.

BioCryst will receive $70 million (€64.8 million) upfront, up to $275 million (€254 million) in future regulatory and sales milestone payments, and tiered royalties on sales ranging from 18 to 30%. Neopharmed Gentili's Irish affiliate will be responsible for securing European regulatory approval for navenibart.

Charlie Gayer, president and chief executive of BioCryst, said: "This deal enables both companies to build upon the strong foundation of Orladeyo and leverages Neopharmed Gentili's expertise in Europe to drive continued execution and positive patient outcomes in the territory."

Alessandro Del Bono, chief executive of Neopharmed Gentili, said the agreement accelerates the company's long-term growth trajectory and consolidates its position as a leading European company in the field of rare diseases.

Navenibart is an investigational long-acting inhibitor of plasma kallikrein, an enzyme involved in hereditary angioedema. BioCryst acquired the asset in January through its $700 million (€647 million) purchase of Boston-based Astria Pharmaceuticals and is conducting a Phase 3 clinical programme, with US regulatory approval targeted by end of 2027.

The agreement builds on a 2025 deal between the two companies covering European commercialisation of BioCryst's approved oral HAE treatment Orladeyo. Hereditary angioedema affects an estimated 10,000 to 50,000 people across Europe.

Read the complete report for further detail on the BioCryst and Neopharmed Gentili licensing agreement.